ADXS > Advaxis Provides 2016 Business Outlook 11 Trials Evaluating Lm Technology™ Advance to Hit Multiple Development Milestones PD-1 and PD-L1 Checkpoint Combination Trials Advance to Second Phases of Evaluation Phase 3 AIM2CERV Trial to Commence in mid-2016 MINE™ (My Immunotherapy Neo-Epitopes) Progresses to Clinical Evaluation http://ir.advaxis.com/press-releases/detail/1196